Boryung-Lilly jointly sell weekly GLP-1 analogue, ‘Trulicity’

Published: 2016-06-09 13:32:51

Updated: 2016-06-09 13:32:51

On the 7^th, Boryung Pharm(CEO Tae-hong Choi) and Lilly Korea(CEO Paul Henry Huibers) announced conclusion of the joint sales agreement for domestic marketing and sales of ‘Trulicity(generic name: dulaglutide),’ a weekly GLP-1(glucagon-like peptide-1) analogue.

Based on the respective marketing and sales infrastructure, Boryung Pharm and Lilly Korea plan to increase treatment accessibility for...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.